Key Takeaways
- • Bain Capital acquires Vitabiotics for approximately £900 million, marking a significant expansion into the UK-headquartered vitamins, minerals and supplements (VMS) sector with established consumer brands and global distribution reach.
- • Deal encompasses UK operations plus the broader VB Group, including Meyer Organics in India and African operations (VB Egypt), positioning Bain to leverage geographic diversification across high-growth markets including India, China, the Middle East and North Africa.
- • Vitabiotics generated approximately £275 million in sales during its 2025 financial year and maintains market leadership through consumer-recognized brands including Pregnacare, Perfectil, Wellman, Wellwoman, and Osteocare, with distribution across more than 70 countries.
- • Bain Capital's Asia Private Equity team will lead the investment, supported by the firm's global platform, signaling focus on leveraging regional expertise to accelerate international expansion and strengthen emerging market positions.
- • UK operations will remain central to the brand, with no immediate operational changes planned, preserving the company's innovation and category leadership positioning while enabling capital deployment for R&D, manufacturing and digital engagement.
Summary
Bain Capital has agreed to acquire Vitabiotics, the UK's leading independent vitamin and supplements manufacturer, in a transaction valued at approximately £900 million. The acquisition encompasses Vitabiotics' UK operations alongside the broader VB Group infrastructure, including Meyer Organics in India and regional operations across Africa such as VB Egypt. The deal positions Bain Capital to accelerate international expansion across key VMS markets while consolidating a portfolio of established consumer health brands with significant retail penetration.
Founded in 1971 by Professor Kartar Lalvani OBE, Vitabiotics has established itself as a British health staple with market-leading positions across multiple consumer segments. The company's portfolio includes recognizable brands such as Pregnacare, Perfectil, Wellman, Wellwoman, and Osteocare, with products distributed through nearly every UK pharmacy and supermarket. The company maintains global reach, exporting to more than 70 countries and generating approximately £275 million in revenue during its 2025 financial year.
The investment will be led by Bain Capital's Asia Private Equity team in coordination with the firm's broader global platform. This structure reflects strategic emphasis on deploying local market knowledge and operational expertise in India and other emerging markets including China, the Middle East and North Africa. Vitabiotics' combination of scientific credibility, established consumer recognition, and existing international distribution infrastructure positions it as an attractive platform for geographic expansion within the VMS sector.
Bain Capital emphasized that the UK market will remain central to Vitabiotics' brand identity, innovation strategy, and category leadership, with no immediate changes to day-to-day operations planned. The transaction provides Vitabiotics with access to capital and strategic support for accelerated global expansion, research and development initiatives, manufacturing optimization, and digital engagement enhancements. For the nutraceutical sector broadly, the acquisition underscores institutional investor interest in established consumer health brands combining scientific positioning with strong brand recognition and established distribution networks.
Founded in 1971 by Professor Kartar Lalvani OBE, Vitabiotics has established itself as a British health staple with market-leading positions across multiple consumer segments. The company's portfolio includes recognizable brands such as Pregnacare, Perfectil, Wellman, Wellwoman, and Osteocare, with products distributed through nearly every UK pharmacy and supermarket. The company maintains global reach, exporting to more than 70 countries and generating approximately £275 million in revenue during its 2025 financial year.
The investment will be led by Bain Capital's Asia Private Equity team in coordination with the firm's broader global platform. This structure reflects strategic emphasis on deploying local market knowledge and operational expertise in India and other emerging markets including China, the Middle East and North Africa. Vitabiotics' combination of scientific credibility, established consumer recognition, and existing international distribution infrastructure positions it as an attractive platform for geographic expansion within the VMS sector.
Bain Capital emphasized that the UK market will remain central to Vitabiotics' brand identity, innovation strategy, and category leadership, with no immediate changes to day-to-day operations planned. The transaction provides Vitabiotics with access to capital and strategic support for accelerated global expansion, research and development initiatives, manufacturing optimization, and digital engagement enhancements. For the nutraceutical sector broadly, the acquisition underscores institutional investor interest in established consumer health brands combining scientific positioning with strong brand recognition and established distribution networks.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.